The great uninsuring: Business Insider
Gianna Beasley panicked when she learned her insurer would stop covering Mounjaro. The 29-year-old has polycystic ovarian syndrome and has suffered from debilitating joint pain. Her symptoms had progressed to a point where she was struggling to function.
"I had tried all the medications that existed, supplements on top of supplements, and nothing really was able to fully grasp the insulin resistance piece for me," Beasley says. It was a "complete 180 for my body."
Roughly two years later, Beasley's insurer ended her coverage for GLP-1s because she isn't diabetic, putting her use of the drug in the "lifestyle management" category. In January, she paid $1,800 out of pocket for a one-year supply of generic tirzepatide from a compound pharmacy, according to documents viewed by Business Insider. "It's not a vanity drug," she says. "It's a critical medication."
Nearly five years after GLP-1s hit the market as a treatment for weight loss, their skyrocketing popularity has caught insurers off guard. They've responded by tightening eligibility, adding administrative hurdles, or dropping coverage altogether. And it's not just GLP-1s. Insurers are quietly canceling or restricting coverage for all kinds of cutting-edge treatments, from immunotherapy to mental healthcare to IVF.
The gap between what medicine can do and what insurance will cover is only getting wider — and even those with "good" insurance are being left with overwhelming bills.
Read the full story: https://www.businessinsider.com/lost-100-pounds-zepbound-insurance-denials-ozempic-cancer-2026-4